Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from ImExHS Limited ( (AU:IME) ) is now available.
IMEXHS reported full-year 2025 revenue of $29.0 million, up 10% on the prior year and above guidance, with underlying EBITDA tripling to $1.6 million as recurring revenue, annualised recurring revenue and cash all improved while debt fell. The company processed 8.2 million studies with near-perfect uptime, advanced deployment of its Aquila+ platform, expanded its partner programme, turned around its RIMAB radiology unit and signalled a strategic focus on accelerating higher-margin software growth while pursuing only strongly profitable radiology contracts amid healthcare budget pressures.
The most recent analyst rating on (AU:IME) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
More about ImExHS Limited
IMEXHS Limited (ASX: IME) is an innovative provider of cloud-based medical imaging software and radiology services operating across 18 countries. The company focuses on delivering imaging platforms such as Aquila+ and related radiology solutions to hospitals, clinics and diagnostic centres, with a growing partner-led distribution network supporting its international expansion.
Average Trading Volume: 17,841
Technical Sentiment Signal: Hold
Current Market Cap: A$21.89M
See more data about IME stock on TipRanks’ Stock Analysis page.